Patents by Inventor Mirella G. Zulueta

Mirella G. Zulueta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes
    Patent number: 11578368
    Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 14, 2023
    Assignee: Patia Biopharma, S.A. De C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta
  • Methods, tools and systems for the prediction and assessment of gestational diabetes
    Patent number: 11085082
    Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 10, 2021
    Assignee: Patia Biopharma S.A. de C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
  • METHODS, TOOLS AND SYSTEMS FOR THE ASSESSMENT, PREVENTION, MANAGEMENT AND TREATMENT SELECTION FOR TYPE 2 DIABETES
    Publication number: 20200318192
    Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 8, 2020
    Applicant: Patia Biopharmia, S.A. De C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta
  • METHODS, TOOLS AND SYSTEMS FOR THE PREDICTION AND ASSESSMENT OF GESTATIONAL DIABETES
    Publication number: 20200283850
    Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.
    Type: Application
    Filed: December 16, 2016
    Publication date: September 10, 2020
    Applicant: Patia Biopharma, S.A. de C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
  • METHODS, TOOLS AND SYSTEMS FOR THE ASSESSMENT, PREVENTION, MANAGEMENT AND TREATMENT SELECTION FOR TYPE 2 DIABETES
    Publication number: 20180094318
    Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11—rs75493593; HNF1A—rs483353044; TCF7L2—rs7903146; CDKN2A/B—rs10811661; CDKAL1—rs7756992; SLC30A8—rs3802177; IGF2BP2—rs4402960; FTO—rs9936385; PPARG—rs1801282; HHEX/IDE—rs1111875; ADCY5—rs11717195; JAZF1—rs849135; WSF1—rs4458523; INS—IGF2—rs149483638; KCNQ1—rs2237897; and KCNJ11—rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.
    Type: Application
    Filed: March 18, 2016
    Publication date: April 5, 2018
    Applicant: Patia Biopharmia, S.A. De C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta